# Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

> **NCT00979992** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 35 (actual)

## Conditions studied

- Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Sunitinib Malate

## Key facts

- **NCT ID:** NCT00979992
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-19
- **Primary completion:** 2014-05-01
- **Final completion:** 2019-02-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2020-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00979992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00979992, "Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00979992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*